Ocular Therapeutix, Inc. (FRA:0OT)

Market Cap	1.64B +31.9%
Revenue (ttm)	47.54M -9.2%
Net Income	-212.80M
EPS	-1.23
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	208
Open	8.80
Previous Close	9.21
Day's Range	8.80 - 8.90
52-Week Range	5.41 - 13.66
Beta	n/a
RSI	30.64
Earnings Date	Mar 6, 2026

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 274
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0OT

Financial Performance

In 2024, Ocular Therapeutix's revenue was $63.72 million, an increase of 9.03% compared to the previous year's $58.44 million. Losses were -$193.51 million, 139.7% more than in 2023.

Financial numbers in USD